DK1154786T3 - Sammensætninger til modulering af mucus-sekretionen - Google Patents

Sammensætninger til modulering af mucus-sekretionen

Info

Publication number
DK1154786T3
DK1154786T3 DK00912034T DK00912034T DK1154786T3 DK 1154786 T3 DK1154786 T3 DK 1154786T3 DK 00912034 T DK00912034 T DK 00912034T DK 00912034 T DK00912034 T DK 00912034T DK 1154786 T3 DK1154786 T3 DK 1154786T3
Authority
DK
Denmark
Prior art keywords
mucus secretion
compositions
modulating
modulating mucus
secretion
Prior art date
Application number
DK00912034T
Other languages
Danish (da)
English (en)
Inventor
Linda D Martin
Yuehua Li
Kenneth B Adler
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Application granted granted Critical
Publication of DK1154786T3 publication Critical patent/DK1154786T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00912034T 1999-02-24 2000-02-24 Sammensætninger til modulering af mucus-sekretionen DK1154786T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25615499A 1999-02-24 1999-02-24
PCT/US2000/005050 WO2000050062A2 (fr) 1999-02-24 2000-02-24 Methodes et compositions alterant la secretion de mucus

Publications (1)

Publication Number Publication Date
DK1154786T3 true DK1154786T3 (da) 2005-02-14

Family

ID=22971264

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04024019.4T DK1538162T3 (da) 1999-02-24 2000-02-24 Sammensætninger til ændring af slimsekretion
DK00912034T DK1154786T3 (da) 1999-02-24 2000-02-24 Sammensætninger til modulering af mucus-sekretionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04024019.4T DK1538162T3 (da) 1999-02-24 2000-02-24 Sammensætninger til ændring af slimsekretion

Country Status (10)

Country Link
EP (2) EP1538162B1 (fr)
JP (2) JP5620037B2 (fr)
AT (2) ATE553121T1 (fr)
AU (1) AU766800B2 (fr)
CA (1) CA2366951A1 (fr)
DE (1) DE60014856T2 (fr)
DK (2) DK1538162T3 (fr)
ES (2) ES2391225T3 (fr)
PT (1) PT1154786E (fr)
WO (1) WO2000050062A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
CA2452123A1 (fr) * 2001-06-26 2003-03-01 North Carolina State University Peptide bloquant agissant sur la secretion de mediateurs inflammatoires par les cellules
US6943021B2 (en) * 2002-06-07 2005-09-13 Mattek Corporation Three dimensional vaginal tissue model containing immune cells
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
CA2595406C (fr) * 2005-01-20 2017-07-11 Biomarck Pharmaceuticals, Ltd. Inhibiteur de l'hypersecretion de mucine fonde sur la structure des peptides mans et methodes d'utilisation
WO2006086681A2 (fr) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methodes d'inhibition de la migration et de la proliferation des cellules musculaires lisses
RU2423376C2 (ru) * 2006-07-26 2011-07-10 Байомарк Фармасьютикалз, Лтд. Способы ослабления высвобождения медиаторов воспаления и пептиды, применяемые для этой цели
US11119093B2 (en) * 2013-12-20 2021-09-14 President And Fellows Of Harvard College Low shear microfluidic devices and methods of use and manufacturing thereof
WO2016011301A1 (fr) * 2014-07-17 2016-01-21 The Regents Of The University Of Colorado, A Body Corporate Compositions, procédés et utilisations de nouveaux anticoagulants dans la voie de coagulation
WO2020257162A1 (fr) 2019-06-17 2020-12-24 Biomarck Pharmaceuticals Ltd. Peptides et méthodes d'utilisation de ceux-ci dans le traitement de l'uvéite
WO2022020985A1 (fr) * 2020-07-27 2022-02-03 上海市公共卫生临床中心 Méthode et application pour prévenir et traiter des maladies infectieuses des voies respiratoires en utilisant une membrane de cellule épithéliale des voies respiratoires
WO2023150791A1 (fr) * 2022-02-07 2023-08-10 Biomarck Pharmaceuticals, Ltd. Peptides et leurs méthodes d'utilisation dans le traitement de troubles oculaires

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
CA2093125C (fr) * 1990-10-02 2003-12-16 Warner-Lambert Company Antagonistes de l'angiotensine ii
WO1993000353A1 (fr) * 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences caracteristiques de produit de transcription de genes humains
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (fr) * 1992-01-07 1993-07-14 National University Of Singapore Protéine phosphatase inhibiteur pour l'utilisation en thérapeutique
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
AU709559B2 (en) * 1994-04-07 1999-09-02 Proteinix Company Vasoactive intestinal polypeptide

Also Published As

Publication number Publication date
ES2391225T3 (es) 2012-11-22
HK1041654A1 (en) 2002-07-19
PT1154786E (pt) 2005-02-28
JP2015007065A (ja) 2015-01-15
DK1538162T3 (da) 2012-07-23
CA2366951A1 (fr) 2000-08-31
WO2000050062A2 (fr) 2000-08-31
EP1154786B1 (fr) 2004-10-13
WO2000050062A3 (fr) 2000-12-21
AU766800B2 (en) 2003-10-23
DE60014856D1 (de) 2004-11-18
ATE553121T1 (de) 2012-04-15
EP1538162A3 (fr) 2005-06-15
DE60014856T2 (de) 2006-02-02
EP1538162B1 (fr) 2012-04-11
AU3383300A (en) 2000-09-14
ES2230078T3 (es) 2005-05-01
JP5620037B2 (ja) 2014-11-05
EP1538162A2 (fr) 2005-06-08
JP2002538783A (ja) 2002-11-19
ATE279206T1 (de) 2004-10-15
EP1154786A2 (fr) 2001-11-21

Similar Documents

Publication Publication Date Title
DE60014856D1 (de) Zusammensetzungen zur modulierung der schleimsekretion
MY129356A (en) Electrospun pharmaceutical compositions
ATE312843T1 (de) Neues cyclosporin mit verbesserter wirkung
NO20064159L (no) Nye, biologisk aktive polypeptider, deres fremstilling og farmasoytiske preparater inneholdende polypeptidene
AU7328601A (en) Skin care compositions containing silicone elastomers
ES2300276T3 (es) P40 de interleuquina-12 de mamifero e interleuquina b30. sus combinaciones. anticuerpos. usos en composiciones farmaceuticas.
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
ATE291901T1 (de) Neue omeprazole und (s)-omeprazole zusammensetzung
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
DE69831504T2 (de) Orale verabreichungsform enthaltend einen protonenpumpeninhibitor (z.b.pantoprazole)
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DK1003486T3 (da) Farmaceutisk præparat indeholdende et bruse-syre-basepar
DK0881906T4 (da) Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser
UA72884C2 (uk) Стабілізовані розчини паратирину
BR0009678A (pt) Compostos, composição farmacêutica, e, uso de compostos
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
DE60135261D1 (de) Arzneimittel, welches ein Peptid kleiner oder mittlerer Grösse enthält
DE69528531D1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
ES2194237T3 (es) Preparaciones cosmeticas.
NZ516413A (en) Extended release dose regimens for lasofoxifene ((-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol)
ES2064398T3 (es) Un nuevo antibiotico, mersacidina, un procedimiento para su preparacion y su utilizacion como medicamento.
DE69938130D1 (de) Neue peptide
DE69727583D1 (de) Vermeidung von gastrointestinaler schädigung